Experimental drug aims to shrink kaposi sarcoma lesions
NCT ID NCT07539454
First seen Apr 25, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This study tests a drug called nirogacestat in 28 people with Kaposi sarcoma (KS) that affects the skin. The drug blocks a protein that helps cancer cells grow, with the goal of shrinking tumors and preventing new ones. While current treatments can help, there is no cure for KS, and this trial focuses on controlling the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Siteman Cancer Center at Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.